Pfizer beats fourth quarter profit estimates on robust drug demand
Feb 3(Reuters) - Pfizer on Tuesday reported fourth-quarter profit above Wall Street estimates, boosted by sustained demand for older drugs such as blood thinner Eliquis and heart disease drug Vyndaqel.
On an adjusted basis, the company reported a profit of 66 cents per share, compared to analysts estimates of 57 cents per share, according to data compiled by LSEG.
(Reporting by Sneha S K in Bengaluru; Editing by Anil D'Silva)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BitGo CEO Says Firms Fighting CLARITY Act May Need It Most
Wall Street futures remain muted as traders monitor oil prices and upcoming inflation data
Shiba Inu: This Copper/Gold Chart Shows an Imminent SHIB Bounce
Trending news
MoreCrypto prices
More
